Drug intelligence / Profile preview

avelumab + fulvestrant + palbociclib

Development stage: Unknown
Lead developer: Dana-Farber Cancer Institute
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Intramuscular, Oral

Overview

A combination therapy consisting of avelumab (a PD-L1 inhibitor), fulvestrant (an estrogen receptor antagonist), and palbociclib (a CDK4/6 inhibitor). This triple combination is being investigated for the treatment of hormone receptor-positive (HR+), HER2-negative metastatic breast cancer in patients who have progressed on prior endocrine therapy and CDK4/6 inhibitors.

Targets

CDK6 (Cyclin-dependent kinase 6)CD274 (Programmed cell death protein 1 ligand 1)CDK4 (Cyclin-dependent kinase 4)ESR1 (ERα)

Beyond the preview

Go deeper on avelumab + fulvestrant + palbociclib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on avelumab + fulvestrant + palbociclib.

Explore the full profile